JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5201
Navitas Semiconductor
NVTS
$3.26B
| $233K | ﹤0.01% |
65,140
-51,277
| -44% | -$143K |
2022 Q2
10 quarters
|
|
5202
AMREP Corp
AXR
$115M
| $232K | ﹤0.01% |
7,390
+5,514
| +294% | +$178K |
2023 Q3
5 quarters
|
|
5203
Value Line
VALU
$380M
| $231K | ﹤0.01% |
4,382
+2,819
| +180% | +$144K |
2017 Q4
28 quarters
|
|
5204
Angi Inc
ANGI
$245M
| $231K | ﹤0.01% |
13,914
-8,903
| -39% | -$190K |
2018 Q4
24 quarters
|
|
5205
Prospect Capital
PSEC
$1.07B
| $231K | ﹤0.01% |
53,527
-15,327
| -22% | -$73.5K |
2015 Q2
38 quarters
|
|
|
GOCO
5206
DELISTED
GoHealth
GOCO
| $230K | ﹤0.01% |
17,195
+8,758
| +104% | +$99.6K |
2020 Q4
16 quarters
|
|
5207
Capricor Therapeutics
CAPR
$520M
| $230K | ﹤0.01% |
16,680
-39,519
| -70% | -$692K |
2024 Q1
3 quarters
|
|
5208
Zevra Therapeutics
ZVRA
$593M
| $229K | ﹤0.01% |
27,490
+9,225
| +51% | +$78.7K |
2021 Q2
14 quarters
|
|
|
BOLD
5209
Boundless Bio
BOLD
$59.6M
| $229K | ﹤0.01% |
78,895
+68,959
| +694% | +$201K |
2024 Q2
2 quarters
|
|
5210
BigBear.ai
BBAI
$1.27B
| $228K | ﹤0.01% |
51,166
+5,591
| +12% | +$12.6K |
2022 Q1
11 quarters
|
|
|
BWAY
5211
Brainsway
BWAY
$503M
| $226K | ﹤0.01% |
47,836
+18,298
| +62% | +$89.1K |
2024 Q2
2 quarters
|
|
5212
iShares MSCI Global Metals & Mining Producers ETF
PICK
$2.43B
| $225K | ﹤0.01% |
6,437
+999
| +18% | +$39.6K |
2022 Q2
10 quarters
|
|
5213
UroGen Pharma
URGN
$2.02B
| $225K | ﹤0.01% |
21,114
-46,948
| -69% | -$562K |
2019 Q2
22 quarters
|
|
5214
First Trust SSI Strategic Convertible Securities ETF
FCVT
$105M
| $222K | ﹤0.01% |
6,039
-792
| -12% | -$29.3K |
2023 Q4
4 quarters
|
|
5215
Invesco CEF Income Composite ETF
PCEF
$776M
| $222K | ﹤0.01% |
11,590
+11,140
| +2,476% | +$217K |
2015 Q4
36 quarters
|
|
5216
CALL
JB Hunt Transport Services
JBHT
$22B
| $222K | ﹤0.01% |
1,300
| – | – |
2024 Q2
2 quarters
|
|
|
5217
PUT
JB Hunt Transport Services
JBHT
$22B
| $222K | ﹤0.01% |
1,300
| – | – |
2023 Q4
4 quarters
|
|
5218
Stoke Therapeutics
STOK
$1.65B
| $220K | ﹤0.01% |
19,964
+4,512
| +29% | +$55.4K |
2019 Q3
21 quarters
|
|
5219
DLH Holdings
DLHC
$58.7M
| $220K | ﹤0.01% |
27,386
+23,703
| +644% | +$198K |
2023 Q4
4 quarters
|
|
5220
ProShares UltraShort Bloomberg Natural Gas
KOLD
$179M
| $219K | ﹤0.01% |
5,125
+3,173
| +163% | +$206K |
2024 Q2
2 quarters
|
|
5221
Aclaris Therapeutics
ACRS
$646M
| $219K | ﹤0.01% |
88,320
+79,844
| +942% | +$199K |
2017 Q4
28 quarters
|
|
5222
POSCO
PKX
$17.4B
| $218K | ﹤0.01% |
5,034
-1,827
| -27% | -$102K |
2013 Q2
46 quarters
|
|
|
ALTM
5223
CALL
DELISTED
Arcadium Lithium plc
ALTM
| $218K | ﹤0.01% |
+42,500
| New | +$217K |
2024 Q4
0 quarters
|
|
|
ALTM
5224
PUT
DELISTED
Arcadium Lithium plc
ALTM
| $218K | ﹤0.01% |
+42,500
| New | +$217K |
2024 Q4
0 quarters
|
|
5225
FT Vest US Equity Moderate Buffer ETF March
GMAR
$424M
| $217K | ﹤0.01% |
5,797
-11,963
| -67% | -$445K |
2023 Q3
5 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.